This study determines if EU pricing and reimbursement bodies have revised their pricing and reimburs...
Read moreEuropean payers have not considered biosimilars to be comparable to their reference products or full...
Read moreA recent publication from the WHO identifies that EU pharmaceutical drug prices are too high and tha...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read moreNew legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...
Read moreThis issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...
Read moreA recent Biosimilar pricing announcement of 72% discount of an anti-tumour necrosis factor blows con...
Read moreRecent initiatives indicate EU member states are heading for potential centralised drug procurement
Read moreNICE revises biosimilars guidance to conclude that they do not believe that biosimilars are identica...
Read more